Zai Lab (ZLAB) said Thursday that results from the ongoing phase 1a/1b trial of ZL-1310 in people with extensive-stage small cell lung cancer following at least one previous platinum-based chemotherapy treatment showed "promising" objective response rates and safety profile.
The objective response rate was 74% in all tested dose levels of ZL-1310 in people with the disease, the company said.
The firm showcased the data at the conference in Barcelona regarding the current phase 1a part of the research, which involves increasing the dosage of the drug in four different groups, including outcomes from a total of 25 participants.
"ZL-1310 anti-tumor activity was demonstrated across all dose levels," Zai Lab said.
Also, ZL-1310 was "well tolerated across all dose levels with the majority of treatment-emergent adverse events (TEAE) being Grade 1 or 2," the company said.
The shares of Zai Lab were rising past 15% in recent trading.
Price: 33.41, Change: +4.47, Percent Change: +15.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.